Edwards Lifesciences (EW) EBIT (2009 - 2026)

Edwards Lifesciences has reported EBIT for 18 years, with the latest figure at $513.2 million in Q2 2026.

• On a quarterly basis, EBIT rose 24.81% year-over-year to $513.2 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 1.37% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 8.3% from the prior year.
• EBIT was $513.2 million for Q2 2026 at Edwards Lifesciences, up from $477.6 million in the prior quarter.
• The five-year high for EBIT was $513.2 million in Q2 2026, with the low at $151.1 million in Q4 2025.
• Average EBIT over 5 years is $360.9 million, with a median of $366.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 75.42% in 2023, then plunged 51.66% in 2025.
• Over 5 years, EBIT stood at $197.7 million in 2022, then jumped by 75.42% to $346.8 million in 2023, then fell by 9.86% to $312.6 million in 2024, then slumped by 51.66% to $151.1 million in 2025, then surged by 239.64% to $513.2 million in 2026.
• The last three EBIT figures came in at $513.2 million (Q2 2026), $477.6 million (Q1 2026), and $151.1 million (Q4 2025), per Business Quant data.